for our us syndrome of for the is the as resubmitted seizures day acceptance on our and Thank had to Dravet first as today’s to December quarter Brian. for that September pleased you, candidate expect were of review the continued review, associated the end for to accepted target if joining Later NDA XXXX. on the FINTEPLA filing we it’s announced in mid we NDA our product of FDA Accordingly afternoon priority who the everyone FDA the third the with is FINTEPLA, XX, in to call. grants by timeframe, assuming quickly treatment early FDA. the quarter soon Good lead we
our MAA European submitted early and of the authorities. treatment active by the associated syndrome parallel, in In for XXXX with for remained which review Dravet Regulatory FINTEPLA under was accepted seizure
the several review with we within actively Over and to final assessment XXXX. application been in have process their our quarters last towards on engaged opinion assist Europe advanced in their
our expand treatment of order review these in of As regulatory leading of we about the with this, collaborate of the analyze continue syndrome. FINTEPLA submissions the for clinical Dravet support in set to important experts to evidence to body data further
at seizure data In presented Society and October, both prognosis meaningful under we five Annual Meeting frequency the reduction clinically long-term, of for Dravet convulsive syndrome new patients development Childhood the age similar Neurology six. demonstrating highlighting
that in unexplained our as physical in meaningful reductions SUDEP. recognized showed profound Tonic-Clonic trials epilepsy X pooled of it and child well Seizures. analysis can clinical refractor Generalized death they Phase As also a and during often is the This causes injuries fall in seizure as type for two sudden or of clinically seizure
of of to seizures FINTEPLA Phase FINTEPLA on patients, tracts conducted FINTEPLA, information to the interaction imposed a minimum FINTEPLA results or if drug treat X potential and unlikely considering in for and on to on we be to when in Also are approved. physicians require FINTEPLA dose adjustment is This and if ultimately of metabolic used drugs co-administered. will CBD the CBD study combined study shared This CNS meeting, the that CBD. recently shows cannabidiol access
Dravet new XX place which program leg including drug with A Syndrome X test year, Looking Epilepsy December rest of have presentation eight ahead to X for the through analyses in American once breaker have AES. AES will the from the a been again we strong at total upcoming the presentations at clinical Baltimore. presence accepted take of Society, data
we’ll Monday, a and holding the at room data on include host demonstrated events AE seizure scientific clinical Update symposium evidence again December studies. presentations December program. of will also AES the our highlight exhibit long-term funding morning Investor of lunch highlight a X neuro improvements and cognitive FINTEPLA Conference reductions We’ll generated In the be X from an on The new the FINTEPLA conference the be at at in the data of Meeting. to CME evolving many discussion presented associated will addition, the of Sunday, the
in approval will team the syndrome. Zogenix update in of an FINTEPLA Dravet provide US launch on anticipation of The commercial activities
will taking discuss time emerging we potential Meanwhile FINTEPLA the study product assess dynamics and Dravet currently have actual leading the in our place interactions on key to other We clinical we��re programs. the taking through progress with community stakeholders. also advantage of launch
met their We and in have physicians the with community daily. needs complete that challenges and treating to caregivers, in a other opinion been leaders groups, and families participated view of target patients discussions and key key obtain face important order
we continue meeting positive about to clinical generated and [ph] and FINTEPLA Dravet Alkins with addition, In today. players and efficacy data hold the constructive syndrome
capabilities As level FINTEPLA access high to established an of ensure communicated we’ve previously, of also efficient therapy. experience patients initiate our to specialty pharmacy for a
over the the patients patients and in these XXX extension one there for by total, continue are the XXX open-label at at least of Dravet FINTEPLA access safety we years. on with profile the year to and strong encouraged remained studies these We efficacy Dravet demonstrated More for FINTEPLA long-term. processing have these FINTEPLA In XXX being been and and two Importantly, treated in least patients both experience now by community being interest early than program. across over programs. from currently are engagement the
Lennox-Gastaut completed XX for treatment the LGS We global associated quarter double-blind is clinical the years XXX of seizures placebo Study with XXXX and age. Phase of that subjects between and two Moving to syndrome. for a in company’s X-arm our third or enrolment managed XXXX, the Study program FINTEPLA controlled for trial. X we trial
data to first the trial in and XXXX. on quarter line report this from are of track We our efficacy safety top
like gene the need does long-term weeks and by that syndrome study placebo-controlled benchmark This international in disorders. [ph], in criteria mutation then subjects with CDKLX with will I’d double-blind, X Tuberous and [indiscernible] the sodium a for ties study syndrome, randomized, an in now three age short-term indication a Dravet of seizure diagnostic patients channel in briefly to four one trial initiating complex, followed mutations deficiency, syndrome each period new open-label not rare with gene, new PCDHXX sclerosis the discuss will XXXq between be for find clinical seizure exploratory Phase placebo-controlled extension. Doose syndrome. a subjects The multi-cohort Dravet years and
first study X first the enroll of We the into patient quarter expect Phase this to in XXXX.
step its In families while Zogenix a we commitment on further completed becoming program progress and developing Modis FINTEPLA disease to the while and addition in Therapeutics. leader patients to and September X, rare transformative acquisition their another leading of major therapies commercializing the took achieving for the
a One disorder devastating the of DNA investigational therapeutic deficiency from bone the TKXd. depletion development candidate or [ph] lead treatment MTXXXX of stage in-late Mitochondrial for is
currently therapies. profound in While is approved disease and presenting The this and normal progressive eating can ages and weakness prevalent all disease muscle of severe as is other functions. and are movement, no that breathing, impairs infants effect often fatal there children young patients more
therapy MTXXXX by overcome Mitochondrial the deficits substrate treatment deoxythymidine to oral DNA restore fixed-dose caused combination an of and disease. deoxycytidine that is to enhancement serves as
has orphan rare the therapy received diseases As and European investigational upholds treatment in Medicines a breakthrough this reminder, designation and in prime from for and designation FDA Europe. from US therapy the pediatric the the Agency drug TKXd
retrospective Outcomes this Muscle compiled patients World study Congress the a Society adult untreated global deficiency. compared with presented Annual to patients October, and patients. set safety the treated pediatric In and and deoxythymidine early were on Copenhagen in in termed deoxycytidine TkX key XX of XX history study RETRO of outcomes efficacy from natural a data data from and we
RETRO the The [ph] particularly treated PYIO difference that patients All most important less which survival highly, and history probability patients analysis was .XXXXX. natural demonstrated remain survival in at controlled the results patients MTXXXX study of significant alive. treated were the reported than between of untreated from
or responses responses including treated some reacquiring independently without breathing respiratory either or without treated walk, our previously are motor, ventilation nourish in mechanical ability feeding of to operational milestones support. subset major motor efficacy lot patients A demonstrated domains. feeding in other the In of addition, ability to cases and end front improved XX% patients support profound the respiratory stabilized and
due findings that the the study retain we from to MTXXXX and after from future of tolerated. related with half for We during increases Two Safety that discontinued an anticipate reverse regulatory XXXX providing this of exciting study and liver regarding asymptomatic program events first majority The and discuss to steps plans patients the indicated RETRO withdrawing, discussions. these development verse to and discontinuation. series treatment underlying timelines disease. well safe enzymes meet to submission FDA once update intent next the feedback are
acceptance our we for NDA in while Dravet at FINTEPLA In Europe. conclusion, for MDMAA syndrome our review and while active remains wait and
key on commercial and launch both United in preparations for Europe. focused States We’re
data look year multiple to in the availability X of disorders. in We of seizure the rare in for X and Phase Phase quarter LGS also the next to first forward initiating study FINTEPLA
pleased and MTXXXX on half recently of the study RETRO to in year. are announced meet very results with the authorities We with next are regulatory also first preparing
call review that, over for Mike? now With to turn the Mike, his financials. I’ll of
